Ethos Technologies
LIFEaTyr Pharma is a public biotherapeutics company (Nasdaq: LIFE) that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases. The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 (NRP2) that downregulates both the innate …
© Wikipedia /
Creative Commons CC-BY-SA 3.0 more at Wikipedia
Insider trades and stock quote 2024-2026
All insider trades at Ethos Technologies
Subscribe RSS| Date | Type | Insider | Position | Ø-Price | Volume |
|---|---|---|---|---|---|
| 1/30/2026 | Sell | Gv, 2017 Gp, L.l.c. | Ten Percent Owner | $19.0 | $35,060,852 |
| 1/30/2026 | Buy | Wheeler, William J. | Director | $19.0 | $4,949,975 |
| 1/30/2026 | Sell | Lantz, Erin N. | Chief Revenue Officer | $17.9 | $2,905,411 |
| 1/30/2026 | Sell | Kucharski, Brandt Walter | Chief Accounting Officer | $17.9 | $221,964 |
| 1/30/2026 | Sell | Sharma, Vipul | Chief Technology Officer | $17.9 | $3,572,000 |
All information without guarantee! No recommendation/consultation!
© U.S. Securities and Exchange Commission (SEC)